118 related articles for article (PubMed ID: 26811678)
1. A new target ligand Ser-Glu for PEPT1-overexpressing cancer imaging.
Dai T; Li N; Zhang L; Zhang Y; Liu Q
Int J Nanomedicine; 2016; 11():203-12. PubMed ID: 26811678
[TBL] [Abstract][Full Text] [Related]
2. AMP-guided tumour-specific nanoparticle delivery via adenosine A1 receptor.
Dai T; Li N; Han F; Zhang H; Zhang Y; Liu Q
Biomaterials; 2016 Mar; 83():37-50. PubMed ID: 26773664
[TBL] [Abstract][Full Text] [Related]
3. Polymeric Nanomedicine for Combined Gene/Chemotherapy Elicits Enhanced Tumor Suppression.
Xu B; Xia S; Wang F; Jin Q; Yu T; He L; Chen Y; Liu Y; Li S; Tan X; Ren K; Yao S; Zeng J; Song X
Mol Pharm; 2016 Feb; 13(2):663-76. PubMed ID: 26695934
[TBL] [Abstract][Full Text] [Related]
4. Influence of PLA-PEG nanoparticles manufacturing process on intestinal transporter PepT1 targeting and oxytocin transport.
Gourdon B; Chemin C; Moreau A; Arnauld T; Delbos JM; Péan JM; Declèves X
Eur J Pharm Biopharm; 2018 Aug; 129():122-133. PubMed ID: 29803721
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of oligopeptide transporter suppress growth of human pancreatic cancer cells.
Mitsuoka K; Kato Y; Miyoshi S; Murakami Y; Hiraiwa M; Kubo Y; Nishimura S; Tsuji A
Eur J Pharm Sci; 2010 Jun; 40(3):202-8. PubMed ID: 20307658
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer.
Dobiasch S; Szanyi S; Kjaev A; Werner J; Strauss A; Weis C; Grenacher L; Kapilov-Buchman K; Israel LL; Lellouche JP; Locatelli E; Franchini MC; Vandooren J; Opdenakker G; Felix K
J Nanobiotechnology; 2016 Dec; 14(1):81. PubMed ID: 27993133
[TBL] [Abstract][Full Text] [Related]
7. Numb/Notch signaling pathway modulation enhances human pancreatic cancer cell radiosensitivity.
Bi YL; Min M; Shen W; Liu Y
Tumour Biol; 2016 Nov; 37(11):15145-15155. PubMed ID: 27677287
[TBL] [Abstract][Full Text] [Related]
8. Dual targeted polymeric nanoparticles based on tumor endothelium and tumor cells for enhanced antitumor drug delivery.
Gupta M; Chashoo G; Sharma PR; Saxena AK; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2014 Mar; 11(3):697-715. PubMed ID: 24512060
[TBL] [Abstract][Full Text] [Related]
9. Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer.
Li W; Ma Z; Ma J; Li X; Xu Q; Duan W; Chen X; Lv Y; Zhou S; Wu E; Ma Q; Huo X
Oncotarget; 2015 Oct; 6(31):31119-33. PubMed ID: 26439801
[TBL] [Abstract][Full Text] [Related]
10. PEPT1 is essential for the growth of pancreatic cancer cells: a viable drug target.
Schniers BK; Rajasekaran D; Korac K; Sniegowski T; Ganapathy V; Bhutia YD
Biochem J; 2021 Oct; 478(20):3757-3774. PubMed ID: 34569600
[TBL] [Abstract][Full Text] [Related]
11. MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway.
Zhou W; Li Y; Gou S; Xiong J; Wu H; Wang C; Yan H; Liu T
Oncotarget; 2015 Nov; 6(35):37557-69. PubMed ID: 26485754
[TBL] [Abstract][Full Text] [Related]
12. Polymer Nanoparticles Modified with Photo- and pH-Dual-Responsive Polypeptides for Enhanced and Targeted Cancer Therapy.
Yang Y; Xie X; Yang Y; Li Z; Yu F; Gong W; Li Y; Zhang H; Wang Z; Mei X
Mol Pharm; 2016 May; 13(5):1508-19. PubMed ID: 27043442
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Akt/NF-κB-regulated inflammation and Akt/Bad-related apoptosis signaling pathway involved in hepatic carcinoma process: suppression by carnosic acid nanoparticle.
Tang B; Tang F; Wang Z; Qi G; Liang X; Li B; Yuan S; Liu J; Yu S; He S
Int J Nanomedicine; 2016; 11():6401-6420. PubMed ID: 27942213
[TBL] [Abstract][Full Text] [Related]
14. Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma.
Liu XJ; Li L; Liu XJ; Li Y; Zhao CY; Wang RQ; Zhen YS
Int J Nanomedicine; 2017; 12():5255-5269. PubMed ID: 28769562
[TBL] [Abstract][Full Text] [Related]
15. Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer.
Daman Z; Faghihi H; Montazeri H
Drug Dev Ind Pharm; 2018 Sep; 44(9):1434-1442. PubMed ID: 29619850
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy.
Li D; Fu Z; Chen R; Zhao X; Zhou Y; Zeng B; Yu M; Zhou Q; Lin Q; Gao W; Ye H; Zhou J; Li Z; Liu Y; Chen R
Oncotarget; 2015 Oct; 6(31):31151-63. PubMed ID: 26439804
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer.
Jiang JX; Sun CY; Tian S; Yu C; Chen MY; Zhang H
Tumour Biol; 2016 Oct; 37(10):13893-13902. PubMed ID: 27485116
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic tumor mass in a xenograft mouse model is decreased by treatment with therapeutic stem cells following introduction of therapeutic genes.
Kim DJ; Yi BR; Lee HR; Kim SU; Choi KC
Oncol Rep; 2013 Sep; 30(3):1129-36. PubMed ID: 23807450
[TBL] [Abstract][Full Text] [Related]
19. Barbaloin loaded polydopamine-polylactide-TPGS (PLA-TPGS) nanoparticles against gastric cancer as a targeted drug delivery system: Studies in vitro and in vivo.
Wang YR; Yang SY; Chen GX; Wei P
Biochem Biophys Res Commun; 2018 Apr; 499(1):8-16. PubMed ID: 29534962
[TBL] [Abstract][Full Text] [Related]
20. Dipeptide-modified nanoparticles to facilitate oral docetaxel delivery: new insights into PepT1-mediated targeting strategy.
Du Y; Tian C; Wang M; Huang D; Wei W; Liu Y; Li L; Sun B; Kou L; Kan Q; Liu K; Luo C; Sun J; He Z
Drug Deliv; 2018 Nov; 25(1):1403-1413. PubMed ID: 29890854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
